VitroCap N
Ankamah et al., TVST 2021;10(12):19. Double-blind RCT in symptomatic floaters: P<0.001 reduction in discomfort and objective opacity area; contrast sensitivity P=0.047. [View study]
- Serving:
- 1 capsule
- Key:
- L-lysine 125 mg, Vitamin C 40 mg, Vitis vinifera extract 26.3 mg...
Pros
- Closest match to study protocol
- Double-blind RCT data
- Objective opacity reduction outcome
Cons
- Small trial
- Not FDA-approved for floaters
- Single-center study
Affiliate link — we may earn a commission